Aethlon Medical cleared in India to conduct Phase 1 trial of Hemopurifier

Aethlon Medical announced that it has received clearance from the Drug Controller General of India, the central drug authority in India, to conduct a phase 1 safety, feasibility and dose-finding trial of the company’s Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda or Opdivo. The trial is expected to begin following completion of an internal in vitro binding study of relevant targets, and subsequent approval by the respective Ethics Boards of interested sites in India.